Curtis J R, Goode G C, Herrington J, Urdaneta L E
Clin Nephrol. 1976 Feb;5(2):61-5.
The myocardial cobalt concentration in a patient who died 3 months after treatment with cobalt was 25-80 times greater than the concentration in control samples. Blood cobalt concentrations in maintenance hemodialysis patients who had been treated 13-20 months previously with cobaltous chloride were significantly higher than those in maintenance hemodialysis patients who had not received cobalt. Prospective studies of blood cobalt concentrations in maintenance hemodialysis patients and normal subjects after the administration of cobaltous chloride were carried out. It was found that prolonged elevation of blood cobalt concentrations occurred in both normals and maintenance hemodialysis patients, but that the blood cobalt concentrations were much higher in the dialysis patients. The urinary excretion of cobalt following the administration of a single dose of cobaltous chloride was studied in two normal subjects. Cobalt metabolism and toxicity are discussed. In view of the limited therapeutic gains to be expected and because of the lack of information regarding the long term significance of elevated blood cobalt concentrations, it is concluded that cobalt should not be used in the treatment of the anemia of patients with sever renal failure.
接受钴治疗3个月后死亡的患者心肌中的钴浓度比对照样本中的浓度高25至80倍。13至20个月前接受过氯化钴治疗的维持性血液透析患者的血钴浓度显著高于未接受钴治疗的维持性血液透析患者。对维持性血液透析患者和正常受试者在给予氯化钴后血钴浓度进行了前瞻性研究。结果发现，正常人和维持性血液透析患者的血钴浓度都会出现长时间升高，但透析患者的血钴浓度要高得多。对两名正常受试者给予单剂量氯化钴后钴的尿排泄情况进行了研究。对钴的代谢和毒性进行了讨论。鉴于预期的治疗效果有限，且由于缺乏关于血钴浓度升高的长期意义的信息，得出的结论是，钴不应被用于治疗严重肾衰竭患者的贫血。
